Pfizer's Covid-19 vaccine has 'favourable safety profile responses in children 5 to 11'

play article
Subscribers can listen to this article
the trial included 2,268 participants between the ages of 5 and 11 years. (Getty Images)
the trial included 2,268 participants between the ages of 5 and 11 years. (Getty Images)

In a statement released on Monday, 20 September, Pfizer and BioNTech announced their first Covid-19 vaccine trial results in children younger than 12, "the first from a pivotal trial of any Covid-19 vaccine in children". 

According to the statement, the trial included 2,268 participants between the ages of 5 and 11 years. 

The participants were given "a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older". 

While the findings have yet to be submitted to regulatory agencies for review, Pfizer says results are promising, "showing a favourable safety profile and robust neutralizing antibody responses in children". 

Also read: Vaccination for children over the age of 12 on the cards

"The antibody responses in the participants given 10 µg doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunized with 30 µg doses. The 10 µg dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age," the statement read. 

With the data yet to be reviewed, there's no telling when the Covid-19 vaccine will be made available. However, some international reports speculate that vaccine rollout might occur as early as October 2021 in the US. 

Will you, as a parent, be taking your child for the Covid-19 vaccination once it's available in South Africa?


Share your stories and questions with us via email at Anonymous contributions are welcome.

Don't miss a story!

For a weekly wrap of our latest parenting news and advice sign up to our free Parent24 newsletter.

Follow us, and chat, on Facebook and Twitter.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24